Literature DB >> 19857451

Improving the expression of recombinant soluble HIV Envelope glycoproteins using pseudo-stable transient transfection.

George Sellhorn1, Zachary Caldwell, Christine Mineart, Leonidas Stamatatos.   

Abstract

The Envelope glycoprotein (Env) of the human immunodeficiency virus (HIV) is the target of neutralizing antibodies (NAbs). So far, HIV Env-derived immunogens have not been able to elicit broad neutralizing antibody responses against primary isolates. Identifying conditions that will permit the efficient production of different soluble HIV Env proteins will facilitate a high throughput comparative analysis of the immunogenicity of diverse Env constructs, potentially identifying Env forms that are more conducive to the elicitation of anti-HIV NAbs. Here we compared different cell types, transfection reagents, transfection conditions and different DNA expression vectors on soluble HIV Envelope expression levels. We identified optimal expression conditions and developed a protocol to streamline and maximize production of diverse HIV Env constructs. Using this optimized platform, milligram quantities of purified soluble HIV Env trimer can be routinely achieved in a rapid and cost-effective manner.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19857451     DOI: 10.1016/j.vaccine.2009.10.028

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  33 in total

1.  SSP3 is a novel Plasmodium yoelii sporozoite surface protein with a role in gliding motility.

Authors:  Anke Harupa; Brandon K Sack; Viswanathan Lakshmanan; Nadia Arang; Alyse N Douglass; Brian G Oliver; Andrew B Stuart; D Noah Sather; Scott E Lindner; Kevin Hybiske; Motomi Torii; Stefan H I Kappe
Journal:  Infect Immun       Date:  2014-08-25       Impact factor: 3.441

2.  Immunization of mice with live-attenuated late liver stage-arresting Plasmodium yoelii parasites generates protective antibody responses to preerythrocytic stages of malaria.

Authors:  Gladys J Keitany; Brandon Sack; Hannah Smithers; Lin Chen; Ihn K Jang; Leslie Sebastian; Megha Gupta; D Noah Sather; Marissa Vignali; Ashley M Vaughan; Stefan H I Kappe; Ruobing Wang
Journal:  Infect Immun       Date:  2014-09-29       Impact factor: 3.441

3.  Human Rhinovirus Presenting 4E10 Epitope of HIV-1 MPER Elicits Neutralizing Antibodies in Human ICAM-1 Transgenic Mice.

Authors:  Guohua Yi; Xiongying Tu; Preeti Bharaj; Hua Guo; Junli Zhang; Premlata Shankar; N Manjunath
Journal:  Mol Ther       Date:  2015-06-10       Impact factor: 11.454

4.  IL-33 enhances the kinetics and quality of the antibody response to a DNA and protein-based HIV-1 Env vaccine.

Authors:  Sanghita Sarkar; Michael S Piepenbrink; Madhubanti Basu; Juilee Thakar; Michael C Keefer; Ann J Hessell; Nancy L Haigwood; James J Kobie
Journal:  Vaccine       Date:  2019-03-27       Impact factor: 3.641

5.  A native-like SOSIP.664 trimer based on an HIV-1 subtype B env gene.

Authors:  Pavel Pugach; Gabriel Ozorowski; Albert Cupo; Rajesh Ringe; Anila Yasmeen; Natalia de Val; Ronald Derking; Helen J Kim; Jacob Korzun; Michael Golabek; Kevin de Los Reyes; Thomas J Ketas; Jean-Philippe Julien; Dennis R Burton; Ian A Wilson; Rogier W Sanders; P J Klasse; Andrew B Ward; John P Moore
Journal:  J Virol       Date:  2015-01-14       Impact factor: 5.103

6.  Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D.

Authors:  Andrew T McGuire; Jolene A Glenn; Adriana Lippy; Leonidas Stamatatos
Journal:  J Virol       Date:  2013-12-18       Impact factor: 5.103

7.  Engineering, expression, purification, and characterization of stable clade A/B recombinant soluble heterotrimeric gp140 proteins.

Authors:  George Sellhorn; Zane Kraft; Zachary Caldwell; Katharine Ellingson; Christine Mineart; Michael S Seaman; David C Montefiori; Eliza Lagerquist; Leonidas Stamatatos
Journal:  J Virol       Date:  2011-10-26       Impact factor: 5.103

8.  Improvement of antibody responses by HIV envelope DNA and protein co-immunization.

Authors:  Franco Pissani; Delphine C Malherbe; Jason T Schuman; Harlan Robins; Byung S Park; Shelly J Krebs; Susan W Barnett; Nancy L Haigwood
Journal:  Vaccine       Date:  2013-11-23       Impact factor: 3.641

9.  Adenosine deaminase-1 enhances germinal center formation and functional antibody responses to HIV-1 Envelope DNA and protein vaccines.

Authors:  Ebony Gary; Margaret O'Connor; Marita Chakhtoura; Virginie Tardif; Ogan K Kumova; Delphine C Malherbe; William F Sutton; Nancy L Haigwood; Michele A Kutzler; Elias K Haddad
Journal:  Vaccine       Date:  2020-04-10       Impact factor: 3.641

10.  A functional interaction between gp41 and gp120 is observed for monomeric but not oligomeric, uncleaved HIV-1 Env gp140.

Authors:  Miklos Guttman; Kelly K Lee
Journal:  J Virol       Date:  2013-08-21       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.